A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Clinical trial NCT07129252 · RECRUITING

Trial details

NCT number: NCT07129252
Sponsor: Crinetics Pharmaceuticals Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

SST2-positive Neuroendocrine Neoplasms Neuroendocrine Tumors Neuroendocrine Neoplasm

Start date: 2025-11-26
Primary completion: 2027-08-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.